References
- Bill-Axelson A, Holmberg L, Ruutu M, Garmo H, Stark JR, Busch C, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2011;364:1708–17.
- Wilt TJ, Brawer MK, Jones KM, Barry MJ, Aronson WJ, Fox S, et al. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 2012;367:203–13.
- Stattin P, Holmberg E, Johansson JE, Holmberg L, Adolfsson J, Hugosson J. Outcomes in localized prostate cancer: National Prostate Cancer Register of Sweden follow-up study. J Natl Cancer Inst 2010;102:950–8.
- Outzen M, Brasso K, Martinussen N, Christensen J, Tjønneland A, Friis S, et al. Prostate cancer in Denmark 1978–2009 – trends in incidence and mortality. Acta Oncol 2012; Epub ahead of print.
- Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, Mason MD, et al. The updated EAU guidelines on prostate cancer. Eur Urol 2012;58:74–5.
- Cytron S, Green D, Witzsch U, Nylund P, Bjerklund Johansen TE. Cryoablation of the prostate: technical recommendations. Prostate Cancer Prostatic Dis 2009;12:339–46.
- Donnelly BJ, Saliken JC, Ernst DS, Ali-Ridha N, Brasher PM, Robinson JW, et al. Prospective trial of cryosurgical ablation of the prostate: five-year results. Urology 2002;60:645–9.
- Donnelly BJ, Saliken JC, Brasher PM, Ernst SD, Rewcastle JC, Lau H, et al. A randomized trial of external beam radiotherapy versus cryoablation in patients with localized prostate cancer. Cancer 2010;116:323–30.
- Bahn DK, Lee F, Badalament R, Kumar A, Greski J, Chernick M. Targeted cryoablation of the prostate: 7-year outcomes in the primary treatment of prostate cancer. Urology 2002;60:3–11.
- D'Amico AV, Moul J, Carroll PR, Sun L, Lubeck D, Chen MH. Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. J Clin Oncol 2003;21:2163–72.
- Pitman M, Shapiro EY, Hruby GW, Truesdale MD, Cheetham PJ, Saad S, et al. Comparison of biochemical failure definitions for predicting local cancer recurrence following cryoablation of the prostate. Prostate 2012;72:1802–8.
- Cohen JK, Miller RJ Jr, Ahmed S, Lotz MJ, Baust J. Ten-year biochemical disease control for patients with prostate cancer treated with cryosurgery as primary therapy. Urology 2008;71:515–18.
- Baust JG, Gage AA, Clarke D, Baust JM, Van Buskirk R. Cryosurgery – a putative approach to molecular-based optimization. Cryobiology 2004;48:190–204.
- Gage AA, Baust JG. Cryosurgery for tumors – a clinical overview. Technol Cancer Res Treat 2004;3:187–99.
- Kimura M, Rabbani Z, Mouraviev V, Tsivian M, Vujaskovic Z, Satoh T, et al. Morphology of hypoxia following cryoablation in a prostate cancer murine model: its relationship to necrosis, apoptosis and, microvessel density. Cryobiology 2010;61:148–54.
- Saliken JC, Donnelly BJ, Rewcastle JC. The evolution and state of modern technology for prostate cryosurgery. Urology 2002;60:26–33.
- Jones JS, Rewcastle JC, Donnelly BJ, Lugnani FM, Pisters LL, Katz AE. Whole gland primary prostate cryoablation: initial results from the cryo on-line data registry. J Urol 2008;180:554–8.
- Dhar N, Ward JF, Cher ML, Jones JS. Primary full-gland prostate cryoablation in older men (> age of 75 years): results from 860 patients tracked with the COLD Registry. BJU Int 2011;108:508–12.